Summary
qPCR has been increasingly used in many bioanalytical laboratories to support pharmacokinetic evaluation of nucleic acid based therapies and to support quantitation of biomarkers. Bioanalytical laboratories ten years ago were primarily LC/MS/MS and Immunoassay-focused. Drug development has grown more challenging with higher complexity therapies.
The emergence of RNA biomarker assays and the evolution of cell and gene therapy has led many bioanalytical laboratories to implement qPCR and/or ddPCR. While there are existing papers and recommendations available on how to approach the development and validation of qPCR/ddPCR assays, there has not been any consensus paper that is based on a dialogue amongst bioanalytical scientists. This workshop includes a series of presentations with case studies from CROs that have implemented qPCR/ddPCR in a regulated environment. A critical aspect of the workshop will be open discussion – organizers plan to include as much discussion as presentation.
Learning Objectives
- Understand the various ways the PCT is being used in regulated environments to support clinical trials.
- Understand the key aspects of the development of qPCR/ddPCR assays to enable successful implementation validation.
- Understand the applications of PCR in measurement of nucleic acid biomarkers and the application of context of use principles in those assay validations.
- Understand the applications of PCR in gene therapy trials and how the various assays types are validated.
Programming Committee
Jim McNally, Ph.D., BioAgilytix Labs
Amanda Hays, Ph.D., PRA Health Sciences
Rafiq Islam, Ph.D., Smithers Avanza
Thank you to our workshop sponsors!